[Skip to Content]
[Skip to Content Landing]
January 23, 1967


JAMA. 1967;199(4):31-42. doi:10.1001/jama.1967.03120040013004

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


Burkitt's Lymphoma In United States  ?The histologic twin of one of cancer research's most exciting recent leads—the Burkitt's lymphoma of Africa—has now been confirmed in more than 50 US patients.Although investigators will not yet categorize the malignancy as identical on both continents, the National Cancer Institute has launched an interdisciplinary program to "convert speculation to objective data."Since 1958, when Denis Burkitt, MD, began publishing his studies of the tumor syndrome in equatorial Africa, Burkitt's lymphoma has attracted international interest. The main reasons are two:

  • Long term remissions are possible in about 20% of the African patients with comparatively low chemotherapy doses;

  • Epidemiological and other evidence suggests the carcinogen is a mosquito-borne virus.

The first factor is fact, the second still only speculation. Within the past two years, published reports of "Burkitt-like" tumors in United States residents have appeared (JAMAMedical News192:30 [April 12] 1965).